Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform allows the Company to rapidly screen for disease-modifying therapies to overcome toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s growing pipeline consists of additional programs focused on dementia with Lewy bodies, amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Yumanity disavows any obligation to update the information after the date of their issuance.